ITeos Therapeutics Inc ITOS posted new preclinical data for its anti-TIGIT monoclonal antibody, EOS-448, at the American Society of Hematology (ASH) Annual Meeting & Exposition and the TIGIT Therapies Digital Summit 2021.
- Data at the ASH 2021 demonstrated the efficacy of EOS-448 as a single agent and in combination with an immunomodulatory imide drug (IMiD) in a preclinical model of multiple myeloma.
- The Fc-enabled anti-TIGIT monoclonal antibody elicited effective control of multiple myeloma disease progression, while an Fc-disabled version was inactive.
- Furthermore, the Fc-enabled anti-TIGIT antibody demonstrated synergistic activity when combined with an IMiD.
- Preclinical data shared at TIGIT Therapies Digital Summit highlight evidence for a multifaceted mechanism of action of EOS-448.
- "We look forward to progressing our clinical development plan in 2022 in both multiple myeloma and solid tumors with several combinations," said Michel Detheux, President & CEO.
- Related Link: iTeos Therapeutics Stock Surges On $2.1B Development Pact For EOS-448 With GSK.
- Price Action: ITOS closed 1.38% lower at $34.26 on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in